Next Lesson - Calcium Metabolism
Contents
Abstract
- Diabetes mellitus is the term used for metabolic disorders characterised by chronic hyperglycaemia (high blood glucose). It can be caused by insulin deficiency, insulin resistance (when cells respond poorly to insulin), or both.
- Type 1 diabetes mellitus can start at any age, but new diagnoses peak around puberty and early adulthood. It is thought to be caused by a mixture of genetic and environmental factors.
- Type 2 diabetes mellitus is strongly associated with obesity, and is caused by insulin resistance combined with a gradual decline in insulin secretion by the pancreatic β-cells (the cells that make insulin).
- The classic triad of symptoms of diabetes mellitus is polyuria (passing large volumes of urine), excessive thirst and weight loss. This triad is typical of type 1 diabetes. In type 2 diabetes, symptoms may be mild or absent, and can also include recurrent infections, lack of energy and foot problems.
- Macrovascular (large blood vessel) problems associated with diabetes mellitus include increased risk of stroke, increased risk of myocardial infarction and poor circulation to the periphery.
- Microvascular complications include diabetic nephropathy (kidney damage), diabetic neuropathy (nerve damage), diabetic foot disease and diabetic eye disease.
- Metabolic syndrome is a cluster of risk factors for cardiovascular disease and type 2 diabetes. The features are insulin resistance, dyslipidaemia (abnormal blood fat levels), glucose intolerance (poor handling of glucose) and hypertension, associated with central adiposity (excess fat around the abdomen). It is now a global problem, closely linked to obesity and physical inactivity.
Core
Diabetes Mellitus (DM) is the term used for metabolic disorders characterised by chronic hyperglycaemia (increased plasma glucose levels), which can be caused by insulin deficiency, insulin resistance or both. Diabetes mellitus is typically characterised as either Type 1 or Type 2, distinguished by their epidemiology and probable causation, but the two types can be hard to tell apart clinically. Other types include gestational diabetes (high blood glucose that develops during pregnancy and usually disappears after giving birth), and monogenic diabetes (caused by a change in a single gene). Diabetes can also be caused by another condition or disease.
Type 1 Diabetes Mellitus (T1DM)
T1DM is most common in the young: new diagnoses peak around puberty and early adulthood, but it can start at any age. In adults, NICE advises that age or BMI alone should not be used to diagnose or rule it out. It is an autoimmune condition, which is thought to be caused by a genetic predisposition (susceptibility is determined by multiple genes) combined with an environmental trigger. Together these produce an autoimmune reaction in which lymphocytes, macrophages and auto-antibodies attack and progressively destroy the pancreatic β-cells (the cells that make insulin).
A typical patient would be a lean, young person, with a recent history of viral infection, who presents with a triad of symptoms: polyuria, thirst, and weight loss. This triad of symptoms is very characteristic of T1DM, and is explained below:
- Polyuria (passing large volumes of urine) - the high concentration of glucose in the tubular fluid (the filtered fluid inside the kidney tubules) raises its osmolality (concentration of dissolved particles). Less water is then reabsorbed, so more urine is produced. This is called osmotic diuresis. Glucose also appears in the urine (glycosuria).
- Thirst - losing so much water in the urine dehydrates the body, which triggers thirst.
- Weight Loss - without insulin, cells such as muscle and fat cells cannot take up glucose to use as fuel, so the body breaks down fat and protein for energy instead.
In diabetes the lack of insulin causes decreased uptake of glucose into adipose tissue (fat) and skeletal muscle, and decreased glucose storage as glycogen in muscle and liver. As a result, plasma glucose levels rise. High blood glucose is confirmed by measuring the plasma glucose concentration (see Diagnosing Diabetes below). Type 1 diabetes is then diagnosed on clinical grounds, and in adults NICE recommends testing for diabetes-specific auto-antibodies.
If T1DM is not treated early, patients can develop diabetic ketoacidosis (a dangerous build-up of ketone acids in the blood). A low insulin level, together with a relative excess of the hormones that oppose insulin (such as glucagon), releases fatty acids from fat tissue and drives a high rate of β-oxidation of fats in the liver (the breakdown of fatty acids to release energy). This leads to the production of huge amounts of ketone bodies, such as acetoacetate, acetone, and β-hydroxybutyrate. Acetone is a volatile substance and is therefore breathed out and smelled on the patient’s breath. Symptoms of ketoacidosis include prostration (extreme weakness), hyperventilation (fast, deep breathing), nausea, vomiting, dehydration and abdominal pain.
T1DM cannot be cured and must be managed for the rest of the patient’s life with insulin. This can be given as injections several times a day (usually a basal-bolus regimen: a background insulin plus rapid-acting insulin injected before meals). It can also be given by an insulin pump, a small device attached to the skin that gives insulin throughout the day and night. Living with T1DM has major social and psychological effects, and these can affect how well the condition is controlled. Along with insulin, dietary management and regular exercise must be considered to better manage the condition. NICE recommends offering adults with T1DM a structured education programme, such as DAFNE (dose adjustment for normal eating), and training in carbohydrate counting.
The management of blood glucose requires frequent glucose measurement. NICE recommends offering adults with T1DM a choice of continuous glucose monitoring (CGM) devices (real-time or 'flash'). These measure glucose levels and send the readings to a display device or smartphone. People using CGM still need some finger-prick tests, although less often, for example to check the device's accuracy. Finger-prick testing is also offered to anyone who cannot use or does not want CGM. A small amount of blood from a finger prick is sufficient to measure blood glucose using a BM stick and reader (a test strip and handheld blood glucose meter). However, this method is only accurate if used carefully. Insulin treatment always carries a risk of hypoglycaemia (abnormally low blood glucose). A person who can swallow is treated with fast-acting glucose by mouth. A person who cannot safely take treatment by mouth, for example because they are drowsy or unconscious, is given intramuscular glucagon or IV glucose.

Diagram: An example of a BM stick used by patients with T1DM to measure their own blood glucose levels
Creative commons source by Reversing Your Diabetes Today [CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)]
Type 2 Diabetes Mellitus (T2DM)
T2DM patients are typically older than those diagnosed with T1DM, and are usually overweight. T2DM is generally caused by insulin resistance (when cells respond poorly to insulin), which at first is compensated for by the pancreas increasing insulin production. However, over time pancreatic β-cell function decreases, and the patient suffers hyperglycaemia due to the inability of the pancreas to compensate for insulin resistance. By the time of diagnosis, β-cell function (the β-cells' ability to secrete insulin) has on average already fallen to about half of normal. As β-cell function falls further, problems with insulin resistance and insulin secretion worsen, increasing the patient's hyperglycaemia.
Symptoms may be mild or absent, and when present they may develop gradually. Some patients have the classical triad of symptoms (polyuria, thirst, and weight loss) seen in T1DM. Other symptoms include lack of energy, minor skin damage that is slow to heal, and visual problems such as blurred vision. Persistent infections can also occur, particularly genital thrush (a yeast infection) or infections of the feet.
T2DM can sometimes be managed by diet and exercise alone. However, NICE (updated February 2026) now recommends offering most adults with T2DM two drugs as initial treatment. One is metformin, which mainly reduces glucose production by the liver (gluconeogenesis) and increases glucose use by the tissues. The other is an SGLT-2 inhibitor (sodium-glucose co-transporter 2 inhibitor), which reduces glucose reabsorption in the kidney's proximal tubule so that more glucose is passed in the urine. SGLT-2 inhibitors are recommended as much for their heart and kidney benefits as for lowering glucose, but they have risks. They can cause genital infections such as thrush. Rarely, they can cause diabetic ketoacidosis (even when blood glucose is only moderately raised) or Fournier's gangrene (a rare but serious infection of the genitals or the skin around them). NICE says these risks should be discussed with the person before starting treatment. If further drugs are needed, the choice depends on the person's other conditions, such as heart failure, atherosclerotic cardiovascular disease (artery disease caused by fatty plaques), obesity, chronic kidney disease or frailty (a state of increased vulnerability to illness). For adults with none of these, NICE advises adding a DPP-4 inhibitor first. This is a tablet that blocks the breakdown of incretin hormones, which are gut hormones that help the pancreas to release insulin after meals. If a DPP-4 inhibitor cannot be used, is not tolerated or is not effective, the options are a sulfonylurea, pioglitazone (a tablet that makes the body's cells respond better to insulin) or insulin. Sulfonylureas stimulate β-cells to release insulin but can increase the risk of hypoglycaemia and weight gain. NICE also advises considering a GLP-1 receptor agonist or tirzepatide (medicines that copy the action of incretin hormones) for adults who are living with obesity or who have early onset type 2 diabetes (diagnosed before the age of 40).
In a person with symptoms of diabetes, the following venous plasma glucose criteria support the diagnosis. Without symptoms, an abnormal result requires confirmation as described below.
- A random venous plasma glucose concentration (taken at any time of day, regardless of meals) ≥11.1 mmol/L,
- OR a fasting plasma glucose concentration ≥7.0 mmol/L,
- OR plasma glucose concentration ≥11.1 mmol/L 2 hours after 75g anhydrous glucose in an oral glucose tolerance test (a timed test in which the person drinks a measured amount of glucose).
Without symptoms, a single abnormal glucose result does not establish diabetes. Confirm with at least one further venous plasma glucose result in the diabetic range on another day, using a fasting, random or two-hour post-glucose-load sample. Glycosuria (glucose in the urine) and a finger-prick glucose meter reading alone cannot establish the diagnosis.
HbA1c (glycated haemoglobin, which reflects average blood glucose over the previous 8 to 12 weeks) can also be used to diagnose type 2 diabetes. A result of 48 mmol/mol (6.5%) or more is in the diabetic range. Without symptoms, a single abnormal HbA1c still needs repeat testing, preferably with the same test. HbA1c should not be used to diagnose diabetes in some groups, including people under 18, pregnant women (or women within 2 months after giving birth), people who have had symptoms for less than 2 months and high-risk people who are acutely ill. It also needs careful interpretation when red blood cell turnover or the type of haemoglobin is abnormal, for example in sickle cell trait, severe anaemia or after a recent blood transfusion.
Complications of Diabetes Mellitus
Persistent hyperglycaemia is associated, in some tissues, with the abnormal metabolism of glucose into products that may be harmful to cells. This is because, in some tissues, such as peripheral nerves, the eyes and the kidneys, glucose uptake into cells does not require insulin. Instead, it depends on the extracellular glucose concentration. When a patient is experiencing hyperglycaemia, the intracellular concentration of glucose in these tissues increases. Glucose is then converted to sorbitol (a sugar alcohol) in the following reaction, catalysed by the enzyme aldose reductase. The reaction uses the coenzyme NADPH (nicotinamide adenine dinucleotide phosphate):
Glucose + NADPH + H+ → Sorbitol + NADP+
An increase in the above reaction depletes cellular NADPH, weakening the antioxidant defences of these cells (their protection against chemical damage, which depends on NADPH). This weakened defence allows abnormal disulphide bonds (sulphur-to-sulphur links) to form in cellular proteins, altering their structure and function. In addition, the increased accumulation of sorbitol (a sugar alcohol) causes osmotic damage to cells.
Persistent hyperglycaemia is also associated with the increased glycation of plasma proteins (glucose attaching to proteins). The extent of glycation depends on the glucose concentration and the half-life of the protein. Glycation changes the net charge and 3D structure of the protein, therefore affecting the protein's function. Glucose can react with the terminal valine (the amino acid at the end of a haemoglobin chain) on haemoglobin to form glycated haemoglobin (HbA1c). HbA1c reflects blood glucose control over the previous 8 to 12 weeks. It is therefore used as an indicator of how well diabetes is controlled and how effective treatment has been. NICE guidance gives HbA1c in mmol/mol, with the older percentage in brackets: for example, 48 mmol/mol (6.5%).
People who have had diabetes for a long time can develop a number of macrovascular (large blood vessel) and microvascular (small blood vessel) complications. These complications are made worse in people whose blood glucose is poorly controlled.
Macrovascular complications include increased risk of stroke, increased risk of myocardial infarction and poor circulation to the periphery, particularly to the feet (peripheral arterial disease).
There are a wide range of microvascular complications, which are explained below:
- Diabetic Eye Disease - this is usually caused by diabetic retinopathy, in which hyperglycaemia damages the blood vessels in the retina (the light-sensitive layer at the back of the eye). This damage can lead to blindness. The damaged blood vessels may leak and form hard exudates (deposits of fat and protein that have leaked from the vessels) on the retina, or they can rupture and cause bleeding into the eye. Retinopathy does not usually cause symptoms at first, so in England people with diabetes aged 12 or over are invited for diabetic eye screening every 1 or 2 years. Finding and treating it early reduces the risk of sight loss.
- Diabetic Kidney Disease (Diabetic Nephropathy) - hyperglycaemia damages the renal glomeruli (the kidney's filtering blood vessels). An early sign of diabetic kidney disease is proteinuria (protein in the urine). In people with diabetes this is checked with a urine albumin:creatinine ratio (ACR) test, and a confirmed ACR of 3 mg/mmol or more is regarded as clinically important. Separately, glucose in the urine provides a substrate for bacteria, so urinary tract infections can be more common.
- Diabetic Neuropathy - hyperglycaemia damages peripheral nerves in a number of ways, which can cause a change in or complete loss of sensation.
- Diabetic Foot Disease - three problems combine to damage the feet of people with diabetes: poor blood supply, nerve damage (loss of sensation) and an increased risk of infection. Together they greatly increase the risk of foot damage, such as ulcers. NICE recommends assessing the foot risk of adults with diabetes when diabetes is diagnosed and at least once a year after that.

Diagram: Table outlining the main comparisons between type 1 and type 2 diabetes
SimpleMed original by Dr. Jenny Hubball
Metabolic syndrome is defined as a cluster of risk factors for cardiovascular disease and type 2 diabetes, including insulin resistance, dyslipidaemia, glucose intolerance and hypertension, associated with central adiposity (excess fat around the abdomen). The other features may share a common cause in insulin resistance, as they are commonly found together in patients with T2DM. Metabolic syndrome is seen commonly in the obese, and is related to an increase in obesity-related morbidity. The major factors that predispose the population to metabolic syndrome are obesity and a sedentary lifestyle. These cause insulin resistance, which is associated with a dyslipidaemic profile (↑VLDL, ↑triglycerides, ↓HDL) that is highly atherogenic (it promotes atherosclerosis). VLDL stands for very low-density lipoprotein. Insulin resistance is also associated with an increased risk of hypertension. The WHO (1999) criteria for metabolic syndrome require insulin resistance or abnormal glucose regulation, plus at least two of the other features listed below:
- Glucose (required): type 2 diabetes, impaired fasting glucose (fasting plasma glucose ≥6.1mmol/L), impaired glucose tolerance (plasma glucose ≥7.8mmol/L 2 hours after a glucose load) or other evidence of insulin resistance
- Central obesity, with a waist:hip ratio of >0.9 in men and >0.85 in women, and/or a BMI >30kg/m2
- BP ≥140/90mmHg, or on treatment for high blood pressure
- Triglycerides ≥1.7mmol/L and/or HDL cholesterol <0.9mmol/L in men and <1.0mmol/L in women
- Microalbuminuria (small amounts of the protein albumin in the urine)
Other organisations use different definitions. For example, the International Diabetes Federation (IDF) definition requires central obesity plus at least two other features. It uses different thresholds: fasting glucose ≥5.6mmol/L (or known type 2 diabetes), HDL cholesterol <1.03mmol/L in men and <1.29mmol/L in women, and BP ≥130/85mmHg. Always check which definition is being used.
Metabolic syndrome first became common in Western developed countries, but with the spread of the Western lifestyle it is now a global problem. In one large Finnish and Swedish study using the WHO definition, it was present in 78% of women and 84% of men with type 2 diabetes.
When diagnosing metabolic syndrome, note that BMI does not allow for large muscle bulk. Central fat around the abdomen, not just total body fat, is associated with insulin resistance, fatty liver and the other features of metabolic syndrome. This means that BMI is not an ideal measurement of central fat. NICE therefore recommends measuring waist-to-height ratio as well as BMI in adults with a BMI below 35kg/m2. A ratio of 0.5 to 0.59 indicates increased health risks, and 0.6 or more indicates further increased risks.
Edited by: Dr. Thomas Burnell
Reviewed by: Dr. Marcus Judge
Quiz
- 8937


